Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (CGEN) is a clinical-stage cancer immunotherapy company that regularly issues news on its drug discovery platform, clinical programs, and strategic collaborations. The company emphasizes its predictive AI/ML-powered computational discovery platform, Unigen™, which it uses to identify novel drug targets and biological pathways for immuno-oncology therapies.
News about Compugen often highlights progress across its key clinical-stage assets. Updates include data and trial milestones for COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody, and COM902, a potential best-in-class Fc-reduced high-affinity anti-TIGIT antibody in Phase 1 development. The company also reports on GS-0321 (previously COM503), a potential first-in-class, high-affinity anti-IL-18 binding protein antibody licensed to Gilead, and on rilvegostomig, a PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca under license from Compugen.
Investors following CGEN news can expect coverage of clinical trial initiations and updates, such as the MAIA-ovarian platform trial evaluating COM701 maintenance therapy in relapsed platinum-sensitive ovarian cancer, pooled analyses of Phase 1 trials in platinum-resistant ovarian cancer, and first-in-human studies of GS-0321 in advanced solid malignancies. Company communications also describe partner-led studies of rilvegostomig in indications including non-small cell lung cancer and bladder cancer.
In addition, Compugen’s news flow includes quarterly financial results, cash runway commentary, amendments to collaboration agreements such as royalty monetization transactions with AstraZeneca, and participation in scientific and investor conferences. The CGEN news page on Stock Titan aggregates these announcements so readers can track clinical, financial, and partnership developments from a single source.
Compugen Ltd. (CGEN) announced a strategic shift, prioritizing microsatellite stable-colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC) for development. The company will wind down its Phase 1 cohort expansion studies and conclude its collaboration with Bristol Myers Squibb. Compugen anticipates extending its cash runway through the end of 2024, with approximately $97 million in available cash. R&D expenses remain stable, with a net loss of approximately $9.1 million reported for Q2 2022. The company aims to present further data and study designs in Q4 2022.
Compugen Ltd. (Nasdaq: CGEN) will announce its second quarter financial results on August 4, 2022, before U.S. markets open. A conference call and webcast will take place at 8:30 AM ET for management to discuss the results and provide corporate updates. Compugen is a clinical-stage cancer immunotherapy company focused on computational target discovery, featuring proprietary drug candidates like COM701 and COM902, both in Phase 1 trials. Their partnership with Bayer and AstraZeneca also highlights their innovative drug development.
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy firm, announced its management team's upcoming presentations at industry conferences in Europe. The first event is the 10th Antibody Industrial Symposium in Montpellier, France, on June 28, 2022, featuring Pierre Ferré discussing PVRIG and TIGIT immune checkpoint blockade. The second event is Immuno UK in London on September 29-30, 2022, with Eran Ophir presenting on immunotherapy resistance. Presentation slides will be available on their website.
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced its participation in two upcoming investor conferences. The Jefferies Healthcare Conference will take place in New York City on June 8, 2022, with a fireside chat scheduled for 1:30 PM ET. The JMP Securities Life Sciences Conference is also in New York City on June 15, 2022, at 9:00 AM ET. Live webcasts of both events will be available on Compugen's Investor Relations website.
Compugen Ltd. (CGEN) reported its Q1 2022 financial results, noting a cash balance of $107 million, down from $118 million in Q4 2021. The company continues to execute on its clinical strategy with ongoing Phase 1 studies for COM701 and COM902, aiming for initial data in Q4 2022 related to MSS CRC. COM902 demonstrated a disease control rate of 50%, while R&D expenses were $7.2 million, slightly down year-over-year. Despite a net loss of $9.7 million, the company expects sufficient funds to sustain operations into 2024.
Compugen Ltd. (Nasdaq: CGEN) announced that CFO and COO Ari Krashin will depart the company in August 2022 to pursue other interests. His departure is unrelated to the company's operations or policies. Compugen is a clinical-stage cancer immunotherapy firm known for its predictive computational discovery capabilities, developing drug candidates like COM701 and COM902, targeting various solid tumors. The company maintains partnerships with Bayer and AstraZeneca for its therapeutic programs. Compugen is headquartered in Israel with additional offices in South San Francisco.
Compugen Ltd. (CGEN) will announce its first quarter 2022 financial results on May 16, 2022, before U.S. markets open. The company will not hold a conference call post-release. Additionally, Compugen plans to present a corporate update at two healthcare conferences in June 2022, with more details to follow. Compugen focuses on developing cancer immunotherapies and is currently advancing two product candidates: COM701 and COM902, both in Phase 1 studies.
Compugen Ltd. (CGEN) presented its research on exploring the immune-tumor microenvironment at the Keystone Symposium on March 21, 2022. Using high-resolution single-cell spatial transcriptomics, Compugen revealed insights into immune cell interactions and highlighted the role of the DNAM-1 pathway, including PVRIG, which could help combat immunotherapy resistance. The company leverages a cloud-based computational platform that integrates omics data for drug discovery, enhancing its drug development capabilities in cancer immunotherapy.
Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company, will present insights on the immune-tumor microenvironment at the Keystone Symposium on Cancer Immunotherapy, scheduled for March 20-24, 2022, in British Columbia, Canada. The oral presentation is set for March 21, 2022, titled "Exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics." A poster will also be presented on March 22, 2022, showcasing further findings. More details and the presentation will be available on Compugen's website.
Compugen Ltd. (NASDAQ: CGEN) announced its participation in the Oppenheimer 32nd Annual Global Healthcare Conference on March 16, 2022, at 11:20 am ET. The presentation will be accessible via live webcast on Compugen's Investor Relations page, with a replay available afterward. Compugen specializes in cancer immunotherapy and has developed key products such as COM701 and COM902, both in Phase 1 clinical trials. The company is headquartered in Israel and has a strong pipeline of immuno-oncology programs targeting various immune resistance mechanisms.